AstraZeneca divestment of Movantik to RedHill Biopharma completed
AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma…
Read More...
Read More...
